The Cardiovascular Science & Diabetes (CSVD) Program at the Perkins is jointly led by Professor Shirley Jansen AM and Professor Girish Dwivedi.
The CVSD Program is an integrated research pipeline spanning discovery, biomedical engineering and clinical research, focused on protecting hearts and blood vessels, predicting risks and pioneering cardiovascular disease treatments by:
The priority for the CVSD research team is to advance cardiovascular health and diabetes care by integrating AI_driven technology, biomedical engineering and community-focussed research to reduce the impact of cardiovascular disease.
We have a strong collaborative network with basic, clinical and public health CVD researchers across WA, nationally and internationally.
Researchers in the CVSD Program are based at both Perkins North, adjacent to Sir Charles Gairdner Hospital, and at Perkins South in the Centre for Translational Research on the Fiona Stanley Hospital campus at Murdoch.
Our internationally significant diabetes research has led to new tests to uncover a person’s likelihood of developing diabetes and the severity of its complications, as well as pinpointing genetic markers that will be used to combat the growing epidemic of diabesity.
All donations of $2 and over are tax deductible in Australia.
Perkins is registered with the Australian Taxation Office as a Deductible Gift Recipient (DGR): Charitable Fundraising Authority No DGR CC20761
The Harry Perkins Institute of Medical Research recognises Australia’s first healers and scientists, the Aboriginal and Torres Strait Islander peoples. We acknowledge the Whadjuk people of the Noongar nation, the Traditional Custodians of the lands where we live and work, and pay respects to their elders past and present.